Polysomnographic and pharmacokinetic findings in levodopa-induced augmentation of restless legs syndrome.
Identifieur interne : 001450 ( Ncbi/Curation ); précédent : 001449; suivant : 001451Polysomnographic and pharmacokinetic findings in levodopa-induced augmentation of restless legs syndrome.
Auteurs : Roberto Vetrugno [Italie] ; Manuela Contin ; Agostino Baruzzi ; Federica Provini ; Giuseppe Plazzi ; Pasquale MontagnaSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2006.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Antiparkinson Agents (pharmacokinetics), Disease Progression, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Levodopa (administration & dosage), Levodopa (adverse effects), Levodopa (pharmacokinetics), Metabolic Clearance Rate (physiology), Polysomnography, Restless Legs Syndrome (blood), Restless Legs Syndrome (chemically induced), Restless Legs Syndrome (diagnosis), Restless Legs Syndrome (drug therapy), Spasm (blood), Spasm (chemically induced), Spasm (diagnosis).
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Levodopa.
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , pharmacokinetics : Antiparkinson Agents, Levodopa.
- blood : Restless Legs Syndrome, Spasm.
- chemically induced : Restless Legs Syndrome, Spasm.
- diagnosis : Restless Legs Syndrome, Spasm.
- drug therapy : Restless Legs Syndrome.
- physiology : Metabolic Clearance Rate.
- Aged, Disease Progression, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Polysomnography.
Abstract
Augmentation, defined as a loss of circadian recurrence with progressively earlier daily onset and increase in the duration, intensity, and anatomy of symptoms, not compatible with the half-life of the drug, is associated with dopaminergic treatment in restless legs syndrome (RLS) patients. The pathogenesis of augmentation is unclear. We describe a patient with idiopathic RLS who developed augmentation after 8 months of levodopa treatment. Videopolysomnographic and pharmacokinetic studies with monitoring of plasma levodopa levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with painful dysesthesia. Symptoms and signs of augmentation were related to low plasma levodopa levels, abating 75 minutes after oral levodopa administration and reappearing after 3 hours, closely mirroring the rapid rise and fall of plasma levodopa concentration. This case is the first report in which RLS augmentation is shown to be characterized by motor hyperkinesias paralleling levodopa plasma pharmacokinetic profile.
DOI: 10.1002/mds.20677
PubMed: 16200540
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002E62
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :002E62
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002B64
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001450
Links to Exploration step
pubmed:16200540Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Polysomnographic and pharmacokinetic findings in levodopa-induced augmentation of restless legs syndrome.</title><author><name sortKey="Vetrugno, Roberto" sort="Vetrugno, Roberto" uniqKey="Vetrugno R" first="Roberto" last="Vetrugno">Roberto Vetrugno</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurological Sciences, University of Bologna, Bologna, Italy. vetrugno@neuro.unibo.it</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurological Sciences, University of Bologna, Bologna</wicri:regionArea><wicri:noRegion>Bologna</wicri:noRegion></affiliation></author><author><name sortKey="Contin, Manuela" sort="Contin, Manuela" uniqKey="Contin M" first="Manuela" last="Contin">Manuela Contin</name></author><author><name sortKey="Baruzzi, Agostino" sort="Baruzzi, Agostino" uniqKey="Baruzzi A" first="Agostino" last="Baruzzi">Agostino Baruzzi</name></author><author><name sortKey="Provini, Federica" sort="Provini, Federica" uniqKey="Provini F" first="Federica" last="Provini">Federica Provini</name></author><author><name sortKey="Plazzi, Giuseppe" sort="Plazzi, Giuseppe" uniqKey="Plazzi G" first="Giuseppe" last="Plazzi">Giuseppe Plazzi</name></author><author><name sortKey="Montagna, Pasquale" sort="Montagna, Pasquale" uniqKey="Montagna P" first="Pasquale" last="Montagna">Pasquale Montagna</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="doi">10.1002/mds.20677</idno><idno type="RBID">pubmed:16200540</idno><idno type="pmid">16200540</idno><idno type="wicri:Area/PubMed/Corpus">002E62</idno><idno type="wicri:Area/PubMed/Curation">002E62</idno><idno type="wicri:Area/PubMed/Checkpoint">002B64</idno><idno type="wicri:Area/Ncbi/Merge">001450</idno><idno type="wicri:Area/Ncbi/Curation">001450</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Polysomnographic and pharmacokinetic findings in levodopa-induced augmentation of restless legs syndrome.</title><author><name sortKey="Vetrugno, Roberto" sort="Vetrugno, Roberto" uniqKey="Vetrugno R" first="Roberto" last="Vetrugno">Roberto Vetrugno</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurological Sciences, University of Bologna, Bologna, Italy. vetrugno@neuro.unibo.it</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurological Sciences, University of Bologna, Bologna</wicri:regionArea><wicri:noRegion>Bologna</wicri:noRegion></affiliation></author><author><name sortKey="Contin, Manuela" sort="Contin, Manuela" uniqKey="Contin M" first="Manuela" last="Contin">Manuela Contin</name></author><author><name sortKey="Baruzzi, Agostino" sort="Baruzzi, Agostino" uniqKey="Baruzzi A" first="Agostino" last="Baruzzi">Agostino Baruzzi</name></author><author><name sortKey="Provini, Federica" sort="Provini, Federica" uniqKey="Provini F" first="Federica" last="Provini">Federica Provini</name></author><author><name sortKey="Plazzi, Giuseppe" sort="Plazzi, Giuseppe" uniqKey="Plazzi G" first="Giuseppe" last="Plazzi">Giuseppe Plazzi</name></author><author><name sortKey="Montagna, Pasquale" sort="Montagna, Pasquale" uniqKey="Montagna P" first="Pasquale" last="Montagna">Pasquale Montagna</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (pharmacokinetics)</term><term>Disease Progression</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Levodopa (administration & dosage)</term><term>Levodopa (adverse effects)</term><term>Levodopa (pharmacokinetics)</term><term>Metabolic Clearance Rate (physiology)</term><term>Polysomnography</term><term>Restless Legs Syndrome (blood)</term><term>Restless Legs Syndrome (chemically induced)</term><term>Restless Legs Syndrome (diagnosis)</term><term>Restless Legs Syndrome (drug therapy)</term><term>Spasm (blood)</term><term>Spasm (chemically induced)</term><term>Spasm (diagnosis)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Restless Legs Syndrome</term><term>Spasm</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Restless Legs Syndrome</term><term>Spasm</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Restless Legs Syndrome</term><term>Spasm</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Restless Legs Syndrome</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Metabolic Clearance Rate</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Disease Progression</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Polysomnography</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Augmentation, defined as a loss of circadian recurrence with progressively earlier daily onset and increase in the duration, intensity, and anatomy of symptoms, not compatible with the half-life of the drug, is associated with dopaminergic treatment in restless legs syndrome (RLS) patients. The pathogenesis of augmentation is unclear. We describe a patient with idiopathic RLS who developed augmentation after 8 months of levodopa treatment. Videopolysomnographic and pharmacokinetic studies with monitoring of plasma levodopa levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with painful dysesthesia. Symptoms and signs of augmentation were related to low plasma levodopa levels, abating 75 minutes after oral levodopa administration and reappearing after 3 hours, closely mirroring the rapid rise and fall of plasma levodopa concentration. This case is the first report in which RLS augmentation is shown to be characterized by motor hyperkinesias paralleling levodopa plasma pharmacokinetic profile.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001450 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001450 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:16200540
|texte= Polysomnographic and pharmacokinetic findings in levodopa-induced augmentation of restless legs syndrome.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:16200540" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |